Meg3 inactivation by injection of an AAV9 system carrying Meg3 shRNA into mouse hearts after MI preserved significantly cardiac function, suggesting that knockdown in a cardiomyocytes-specific manner can be achieved using AAV9 systems presenting a promising tool to treat cardiac disease in preclinical models. Here, MEG3 is linked to heart disorder.